Isohashi Fumiaki, Yoshioka Yasuo, Koizumi Masahiko, Konishi Koji, Sumida Iori, Takahashi Yutaka, Ogata Toshiyuki, Morishige Ken-Ichirou, Enomoto Takayuki, Kawaguchi Yoshifumi, Kotsuma Tadayuki, Adachi Kana, Fukuda Shoichi, Akino Yuichi, Inoue Takehiro
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Brachytherapy. 2009 Apr-Jun;8(2):234-239. doi: 10.1016/j.brachy.2008.12.002. Epub 2009 Feb 12.
The aim of the study was to evaluate the results of high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with advanced cervical carcinoma in which intracavitary radiation therapy may result in a suboptimal dose distribution.
Between 1995 and 2005, 25 patients of median age 64 years were treated with external beam radiation therapy and HDR-ISBT. The International Federation of Gynecology and Obstetrics stages of the patients were I (4%), II (16%), III (68%), and IVA (12%). Whole pelvic irradiation of 30Gy/15 fractions was followed by HDR-ISBT of 30Gy/5 fractions/3 days. Subsequently, additional pelvic external beam radiation therapy of 20Gy/10 fractions was delivered with a midline block. The median followup period was 55 months.
The actuarial 5-year progression-free survival and overall survival rates for all cases were 42% and 54%, respectively. For the 17 patients with a Stage III tumor, the 5-year local control and overall survival rates were 73% and 51%, respectively. Two patients (8%) developed late toxicities of Grade 3.
A high rate of pelvic control and survival with acceptable level of late toxicities were obtained for patients with advanced cervical carcinoma treated with HDR-ISBT.
